BDX
Becton, Dickinson and Company NYSE Listed Feb 21, 1973$143.98
+1.67%
vs $141.61
Mkt Cap $52.2B
52w Low $127.59
27.4% of range
52w High $187.35
50d MA $148.96
200d MA $154.07
P/E (TTM)
24.7x
EV/EBITDA
11.7x
P/B
1.6x
Debt/Equity
0.8x
ROE
7.0%
P/FCF
15.5x
RSI (14)
43.80
ATR (14)
$3.13
Beta
0.35
50d MA
$148.96
200d MA
$154.07
Avg Volume
2.9M
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
1 Becton Drive · Franklin Lakes, NJ 07417-1880 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | TNS | 2.78 | 2.90 | +4.3% | 153.26 | +0.4% | -2.5% | -4.2% | +3.0% | -2.3% | +0.2% | — |
| Feb 9, 2026 | TNS | 2.21 | 2.91 | +31.7% | 162.98 | +1.8% | +5.3% | +5.2% | -1.6% | -1.1% | +0.8% | — |
| Nov 6, 2025 | TNS | 3.92 | 3.96 | +1.0% | 109.63 | -0.2% | +0.3% | +2.1% | +4.1% | +1.6% | +0.5% | — |
| Aug 7, 2025 | TNS | 3.40 | 3.68 | +8.2% | 115.99 | -0.4% | +3.1% | -0.5% | +1.3% | +0.5% | -0.5% | — |
| May 1, 2025 | TNS | 3.28 | 3.35 | +2.1% | 104.79 | +1.0% | -0.4% | -1.1% | -1.1% | +1.2% | +0.5% | — |
| Feb 5, 2025 | TNS | 3.00 | 3.43 | +14.3% | 151.46 | -4.7% | -7.3% | +1.2% | -0.1% | +0.0% | -1.6% | — |
| Nov 7, 2024 | TNS | 3.77 | 3.81 | +1.1% | 140.37 | +0.7% | +2.0% | +1.3% | -1.4% | -0.0% | -1.8% | — |
| Aug 1, 2024 | TNS | 3.31 | 3.50 | +5.7% | 145.86 | +0.4% | +2.5% | -2.5% | -0.1% | -1.2% | +0.8% | — |
| May 2, 2024 | TNS | 2.97 | 3.17 | +6.7% | 148.54 | -0.7% | -2.3% | +0.8% | +0.2% | -1.5% | +0.6% | — |
| Feb 1, 2024 | TNS | 2.40 | 2.68 | +11.7% | 149.79 | +1.0% | -2.1% | -0.9% | +1.5% | +0.3% | +0.5% | — |
| Nov 9, 2023 | TNS | 3.42 | 3.42 | +0.0% | 143.55 | +0.7% | +1.0% | +0.5% | -1.1% | +0.2% | +0.6% | — |
| Aug 3, 2023 | TNS | 2.89 | 2.96 | +2.4% | 166.07 | -0.2% | +0.8% | +1.6% | +2.1% | +0.2% | -1.5% | — |
| May 4, 2023 | AMC | 2.75 | 2.86 | +4.0% | 156.04 | +0.8% | +0.5% | -0.8% | -0.7% | +0.6% | +0.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | Evercore ISI | Reiterates | Outperform | $180 | $149.31 | $149.00 | -0.2% | -2.0% | -1.5% | +0.4% | +5.9% | -2.5% |
| Apr 17 | Piper Sandler | Maintains | Neutral → Neutral | — | $154.82 | $155.41 | +0.4% | +2.4% | +0.1% | -1.2% | -0.7% | -0.5% |
| Mar 26 | Piper Sandler | Maintains | Neutral → Neutral | — | $158.27 | $156.83 | -0.9% | -0.6% | -1.8% | +0.1% | +1.6% | -0.6% |
| Mar 23 | Argus | Maintains | Buy → Buy | — | $154.13 | $156.68 | +1.7% | +1.4% | -0.2% | +1.5% | -0.6% | -1.8% |
| Feb 11 | Citigroup | Maintains | Buy → Buy | — | $171.68 | $170.67 | -0.6% | +5.2% | -1.6% | -1.1% | +0.8% | +3.0% |
| Feb 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $162.98 | $165.98 | +1.8% | +5.3% | +5.2% | -1.6% | -1.1% | +0.8% |
| Feb 10 | Citigroup | Maintains | Buy → Buy | — | $162.98 | $165.98 | +1.8% | +5.3% | +5.2% | -1.6% | -1.1% | +0.8% |
| Feb 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $162.98 | $165.98 | +1.8% | +5.3% | +5.2% | -1.6% | -1.1% | +0.8% |
| Feb 10 | Jefferies | Maintains | Buy → Buy | — | $162.98 | $165.98 | +1.8% | +5.3% | +5.2% | -1.6% | -1.1% | +0.8% |
| Feb 10 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $162.98 | $165.98 | +1.8% | +5.3% | +5.2% | -1.6% | -1.1% | +0.8% |
| Feb 10 | JP Morgan | Maintains | Neutral → Neutral | — | $162.98 | $165.98 | +1.8% | +5.3% | +5.2% | -1.6% | -1.1% | +0.8% |
| Jan 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $159.84 | $160.35 | +0.3% | -0.7% | -0.4% | +1.2% | -0.8% | +2.3% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $161.45 | $161.48 | +0.0% | -1.3% | +1.2% | -1.2% | -0.0% | -0.6% |
| Jan 5 | BofA Securities | Maintains | Neutral → Neutral | — | $153.25 | $152.61 | -0.4% | +2.1% | +3.2% | -1.3% | +1.2% | -1.2% |
| Dec 17 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $154.40 | $154.12 | -0.2% | -0.5% | -0.3% | +0.5% | +0.6% | -0.5% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $150.80 | $151.42 | +0.4% | -0.7% | +1.6% | +0.1% | +0.1% | -2.3% |
| Nov 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $109.63 | $109.37 | -0.2% | +0.3% | +2.1% | +4.1% | +1.6% | +0.5% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $109.63 | $109.37 | -0.2% | +0.3% | +2.1% | +4.1% | +1.6% | +0.5% |
| Oct 16 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $115.43 | $112.99 | -2.1% | -0.8% | +2.1% | +1.0% | -1.0% | -0.5% |
| Aug 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $119.59 | $119.62 | +0.0% | -0.5% | +1.3% | +0.5% | -0.5% | +0.5% |
| Aug 8 | Piper Sandler | Maintains | Neutral → Neutral | — | $115.99 | $115.50 | -0.4% | +3.1% | -0.5% | +1.3% | +0.5% | -0.5% |
| Aug 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $115.99 | $115.50 | -0.4% | +3.1% | -0.5% | +1.3% | +0.5% | -0.5% |
| Jun 3 | Barclays | Maintains | Overweight → Overweight | — | $104.70 | $104.28 | -0.4% | +0.7% | +0.2% | +0.1% | +1.4% | -0.5% |
| May 22 | Citigroup | Downgrade | Buy → Neutral | — | $107.01 | $105.72 | -1.2% | -0.5% | -0.5% | +1.8% | -0.9% | +0.5% |
| May 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $103.22 | $103.02 | -0.2% | -1.1% | +1.2% | +0.5% | -0.4% | +4.9% |
| May 2 | Stifel | Maintains | Buy → Buy | — | $104.79 | $105.86 | +1.0% | -0.4% | -1.1% | -1.1% | +1.2% | +0.5% |
| May 2 | Piper Sandler | Downgrade | Overweight → Neutral | — | $104.79 | $105.86 | +1.0% | -0.4% | -1.1% | -1.1% | +1.2% | +0.5% |
| May 1 | William Blair | Downgrade | Outperform → Market Perform | — | $128.00 | $116.10 | -9.3% | -18.1% | -0.4% | -1.1% | -1.1% | +1.2% |
| May 1 | Citigroup | Maintains | Buy → Buy | — | $128.00 | $116.10 | -9.3% | -18.1% | -0.4% | -1.1% | -1.1% | +1.2% |
| Apr 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $123.54 | $125.20 | +1.3% | +1.2% | +1.0% | +0.3% | -0.2% | +0.9% |
| Apr 7 | Barclays | Maintains | Overweight → Overweight | — | $128.14 | $126.56 | -1.2% | -1.1% | -2.1% | +4.2% | -4.9% | +1.3% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $139.06 | $140.45 | +1.0% | -0.1% | +0.1% | +1.1% | +0.2% | -0.2% |
| Jan 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $153.71 | $153.70 | -0.0% | +0.2% | -0.9% | +0.6% | -0.4% | +0.0% |
| Jan 22 | Barclays | Maintains | Overweight → Overweight | — | $148.56 | $147.63 | -0.6% | -1.0% | +1.1% | +1.2% | +2.2% | +0.2% |
| Oct 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $149.01 | $150.68 | +1.1% | +0.2% | -0.8% | -1.0% | +0.4% | -0.3% |
| Oct 1 | Citigroup | Upgrade | Neutral → Buy | — | $149.01 | $150.68 | +1.1% | +0.2% | -0.8% | -1.0% | +0.4% | -0.3% |
| Aug 2 | Raymond James | Maintains | Outperform → Outperform | — | $145.86 | $146.48 | +0.4% | +2.5% | -2.5% | -0.1% | -1.2% | +0.8% |
| Jul 26 | Stifel | Maintains | Buy → Buy | — | $143.88 | $145.11 | +0.9% | +1.9% | +0.2% | +1.6% | -0.3% | -2.1% |
| Jul 10 | Citigroup | Maintains | Neutral → Neutral | — | $136.88 | $136.84 | -0.0% | +1.1% | +0.5% | +1.8% | -1.3% | +2.0% |
| Jul 2 | Evercore ISI | Maintains | Outperform → Outperform | — | $141.70 | $141.57 | -0.1% | -0.0% | -0.2% | -0.5% | -1.0% | -1.8% |
| May 6 | Barclays | Maintains | Overweight → Overweight | — | $145.05 | $146.36 | +0.9% | +0.8% | +0.2% | -1.5% | +0.6% | +0.3% |
| Feb 5 | Barclays | Maintains | Overweight → Overweight | — | $146.60 | $146.47 | -0.1% | -0.9% | +1.5% | +0.3% | +0.5% | +1.3% |
| Jan 3 | Raymond James | Maintains | Outperform → Outperform | — | $151.69 | $151.93 | +0.2% | -2.0% | +1.0% | -0.3% | +2.3% | -4.0% |
| Dec 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $147.25 | $146.67 | -0.4% | -0.3% | -1.7% | -0.1% | +0.0% | -0.5% |
| Nov 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $143.55 | $144.52 | +0.7% | +1.0% | +0.5% | -1.1% | +0.2% | +0.6% |
| Nov 10 | Raymond James | Maintains | Outperform → Outperform | — | $143.55 | $144.52 | +0.7% | +1.0% | +0.5% | -1.1% | +0.2% | +0.6% |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | $169.16 | $169.01 | -0.1% | +0.7% | +0.0% | +0.5% | -0.0% | +1.1% |
| Aug 7 | Barclays | Maintains | Overweight → Overweight | — | $167.37 | $167.74 | +0.2% | +1.6% | +2.1% | +0.2% | -1.5% | +1.8% |
| Aug 4 | Raymond James | Maintains | Outperform → Outperform | — | $166.07 | $165.79 | -0.2% | +0.8% | +1.6% | +2.1% | +0.2% | -1.5% |
| Aug 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $166.07 | $165.79 | -0.2% | +0.8% | +1.6% | +2.1% | +0.2% | -1.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | Garrison Michael DavidOff | EVP & Pres Med.Essntl&BioPharm | Sell | 1,100 | $151.48 | $167K | 14,272 | -0.75% | +1.67% |
| Jun 1, 2026 | Polen Thomas E JrDir/Off | Chairman, CEO and President | Sell | 2,764 | $146.35 | $405K | 110,163 | +2.71% | -2.80% |
| May 26, 2026 | Feld MichaelOff | EVP, Chief Revenue Officer | Sell | 75 | $147.35 | $11K | 21,084 | +0.79% | +0.82% |
| Apr 27, 2026 | Feld MichaelOff | EVP, Chief Revenue Officer | Sell | 74 | $151.94 | $11K | 21,159 | -2.82% | -0.86% |
8-K · 7.01
! Medium
Becton, Dickinson and Company -- 8-K 7.01: Regulation FD Disclosure
May 29
8-K · 2.02
!! High
Waters Corporation -- 8-K 2.02: Earnings Results
Waters Corporation reported Q2 2026 earnings results for the quarter ending April 4, 2026, providing investors with updated financial performance metrics and operational insights.
May 5
8-K · 5.03
! Medium
Becton, Dickinson and Co. -- 8-K 5.03: Amendment to Articles / Bylaws
Becton, Dickinson and Co. amended its bylaws to change its fiscal year, which may affect dividend schedules, earnings reporting timelines, and investor reporting calendars.
Apr 29
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Rick Byrd's retirement after 25 years as a senior executive signals potential leadership transition risks at BD, though investors should monitor whether succession planning adequately addresses any operational or strategic continuity concerns.
Apr 9
8-K
Unknown — 8-K Filing
Becton Dickinson disclosed non-GAAP financial measures in an 8-K filing, suggesting management may be highlighting adjusted metrics that exclude certain charges, which investors should scrutinize to understand actual operational performance.
Apr 2
8-K · 5.02
!!! Very High
CNS Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
CNS Pharmaceuticals loses director Lynne Kelley, effective March 2, 2026, potentially affecting board oversight and governance as the company navigates its pharmaceutical development pipeline.
Mar 2
8-K · 8.01
!! High
Becton, Dickinson and Co. -- 8-K 8.01: Material Event / Announcement
Becton, Dickinson announced pricing for its tender offers on February 25, 2026, upsizing the offer cap for 4.685% Senior Notes, allowing investors to sell debt back to the company at predetermined rates.
Feb 25
8-K · 8.01
!! High
Becton, Dickinson and Co. -- 8-K 8.01: Material Event / Announcement
Becton, Dickinson commenced tender offers for its debt securities, providing investors with an opportunity to sell holdings back to the company at specified prices.
Feb 10
8-K
Becton, Dickinson and Co. -- 8-K Filing
BD expects to complete its combination of Biosciences and Diagnostic Solutions businesses with Waters Corporation today, following stronger-than-expected Q1 performance.
Feb 9
8-K
Waters Corp -- 8-K Filing
Waters separated from Becton Dickinson, paying BD $4.0 billion and issuing 38.5 million shares to BD shareholders upon merger completion.
Feb 9
8-K · 7.01
! Medium
Becton, Dickinson and Co. -- 8-K 7.01: Regulation FD Disclosure
Becton, Dickinson completed previously announced transactions as of February 9, 2026, signaling execution of strategic initiatives that may impact shareholder value through operational changes or portfolio adjustments.
Feb 9
8-K · 5.03
! Medium
Becton, Dickinson and Co. -- 8-K 5.03: Amendment to Articles / Bylaws
Becton, Dickinson issued preferred shares via private placement under Securities Act exemption, expanding its capital structure without public registration.
Feb 5
8-K · 7.01
! Medium
Becton, Dickinson and Co. -- 8-K 7.01: Regulation FD Disclosure
Becton Dickinson reorganized into five focused business segments effective October 1, 2025, potentially improving operational clarity and enabling targeted strategy execution for investors monitoring the medical technology company's performance.
Feb 5
8-K
Augusta SpinCo Corp -- 8-K Filing
This boilerplate disclaimer indicates Augusta SpinCo's securities offering remains subject to regulatory approval and registration requirements across jurisdictions before trading can commence.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | First Eagle Investment Management, Llc | 23,856,222 | $3.8B | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 18,490,610 | $2.9B | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 15,317,242 | $2.4B | New | Mar 2026 |
| 4 | Invesco Ltd. | 10,174,327 | $1.6B | Added | Mar 2026 |
| 5 | Morgan Stanley | 6,749,280 | $1.3B | Reduced | Dec 2025 |
| 6 | Franklin Resources Inc | 5,362,965 | $843M | Added | Mar 2026 |
| 7 | Clearbridge Investments, Llc | 4,140,042 | $651M | Added | Mar 2026 |
| 8 | Jpmorgan Chase & Co | 3,570,324 | $552M | Added | Mar 2026 |
| 9 | Bank Of America Corp /de/ | 2,668,446 | $420M | Reduced | Mar 2026 |
| 10 | Northern Trust Corp | 2,501,559 | $393M | — | Mar 2026 |
| 11 | Nordea Investment Management Ab | 2,435,206 | $376M | Reduced | Mar 2026 |
| 12 | Veritas Asset Management Llp | 2,022,830 | $318M | Reduced | Mar 2026 |
| 13 | First Pacific Advisors, Lp | 1,980,440 | $311M | Added | Mar 2026 |
| 14 | Longview Partners (Guernsey) Ltd | 1,939,236 | $305M | Reduced | Mar 2026 |
| 15 | Bank Of New York Mellon Corp | 1,681,536 | $264M | Reduced | Mar 2026 |
| 16 | Amundi | 1,630,162 | $256M | New | Mar 2026 |
| 17 | Marshall Wace, Llp | 1,587,797 | $250M | Added | Mar 2026 |
| 18 | Ubs Group Ag | 1,422,303 | $224M | Added | Mar 2026 |
| 19 | Liontrust Investment Partners Llp | 1,192,404 | $208M | Added | Mar 2026 |
| 20 | Wells Fargo & Company/mn | 1,269,128 | $200M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$52.16B
Enterprise Value
$58.10B
P/E (TTM)
24.70x
Forward P/E
11.53x
PEG Ratio
-29.05x
P/B
1.63x
P/S
1.89x
P/FCF
15.48x
EV/EBITDA
11.72x
Shares Out
287.1M
Financials (TTM)
Revenue
$21.84B
Net Income
$1.68B
EBITDA
$4.96B
Free Cash Flow
$2.67B
Op Cash Flow
$3.43B
EPS Basic
$5.84
EPS Diluted
$5.83
EPS Forward
$12.49
Gross Margin
45.4%
Op Margin
11.8%
Net Margin
7.7%
Balance Sheet
Total Assets
$55.33B
Total Liab.
$29.94B
Total Equity
$25.39B
Cash
$859.0M
LT Debt
$17.62B
Book Value/Sh
$88.58
Debt/Equity
0.76x
Current Ratio
1.11
Quick Ratio
0.64
Returns & Growth
ROE
7.0%
ROA
3.2%
ROIC
4.7%
Rev Growth YoY
+8.2%
EPS Growth YoY
-0.7%
Price Returns
2W
+1.8%
1M
-1.3%
3M
-16.6%
6M
-3.5%
12M
+8.4%
Technicals
52W High
$187.35
52W Low
$127.59
50d MA
$148.96
200d MA
$154.07
RSI (14)
43.80
ATR (14)
$3.13
Beta
0.35
Avg Volume
2.9M
Dividends
Div Rate
$4.17
Div Yield
2.8%
Frequency
4
Ex-Div Date
Mar 10, 2026
Analyst Price Targets
Consensus
$172.85
High
$202.00
Low
$159.00
Median
$168.01
Data updated apr 24, 2026 9:04pm
· Source: financialmodelingprep.com